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Abstract
Background: Arsenic, a common groundwater pollutant, is associated with adverse reproductive health but few
studies have examined its effect on maternal health.
Methods: A prospective cohort was recruited in Bangladesh from 2008–2011 (N= 1,458). At enrollment (<16 weeks
gestational age [WGA]), arsenic was measured in personal drinking water using inductively-coupled plasma mass
spectrometry. Questionnaires collected health data at enrollment, at 28 WGA, and within one month of delivery.
Adjusted odds ratios (aORs) and 95% confidence intervals (95% CI) for self-reported health symptoms were
estimated for each arsenic quartile using logistic regression.
Results: Overall, the mean concentration of arsenic was 38 μg/L (Standard deviation, 92.7 μg/L). A total of 795
women reported one or more of the following symptoms during pregnancy (cold/flu/infection, nausea/vomiting,
abdominal cramping, headache, vaginal bleeding, or swollen ankles). Compared to participants exposed to
the lowest quartile of arsenic (≤0.9 μg/L), the aOR for reporting any symptom during pregnancy was 0.62 (95%
CI=0.44-0.88) in the second quartile, 1.83 (95% CI= 1.25-2.69) in the third quartile, and 2.11 (95% CI= 1.42-3.13) in
the fourth quartile where the mean arsenic concentration in each quartile was 1.5 μg/L, 12.0 μg/L and 144.7 μg/L,
respectively. Upon examining individual symptoms, only nausea/vomiting and abdominal cramping showed
consistent associations with arsenic exposure. The odds of self-reported nausea/vomiting was 0.98 (95% CI: 0.68,
1.41), 1.52 (95% CI: 1.05, 2.18), and 1.81 (95% CI: 1.26, 2.60) in the second, third and fourth quartile of arsenic relative
to the lowest quartile after adjusting for age, body mass index, second-hand tobacco smoke exposure, educational
status, parity, anemia, ferritin, medication usage, type of sanitation at home, and household income. A positive trend
was also observed for abdominal cramping (P for trend <0.0001). A marginal negative association was observed
between arsenic quartiles and odds of self-reported cold/flu/infection (P for trend= 0.08). No association was
observed between arsenic and self-reported headache (P for trend =0.19).
Conclusion: Moderate exposure to arsenic contaminated drinking water early in pregnancy was associated
with increased odds of experiencing nausea/vomiting and abdominal cramping. Preventing exposure to arsenic
contaminated drinking water during pregnancy could improve maternal health.
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Inorganic arsenic is a ubiquitous environmental pollu-
tant. People can be exposed to arsenic from occupational
activities, eating contaminated foods, and from industrial
sources [1]. The most common route of exposure, how-
ever, is from drinking groundwater that is contaminated
with naturally occurring arsenic [2,3]. In the United
States, a survey of all major aquifers estimated that 7%
of households equating to approximately 4.2 million
people are exposed to arsenic concentrations that exceed
the United States Environmental Protection Agency’s
maximum contaminant level of 10 μg/L [4]. However,
arsenic-contaminated drinking water is a global health
concern particularly for Bangladesh. This is because public
health interventions designed to reduce waterborne dis-
ease switched the population’ss o u r c eo fd r i n k i n gw a t e r
from surface water to groundwater [5]. Unfortunately, the
shallow groundwater aquifer under Bangladesh is contam-
inated with naturally-occurring arsenic [5]. As a result of
this intervention, 46% of the population are exposed to ar-
senic concentrations above the World Health Organiza-
tion’s recommended limit of 10 μg/L and 27% are exposed
to concentrations above 50 μg/L which is the Bangladesh
government’s drinking water recommendation (and previ-
ous U.S. limit) [6].
There is consistent evidence that chronic exposure to
arsenic from drinking water increases the risk of skin
lesions, cardiovascular disease, neuropathy, and type 2
diabetes and cancers of the skin, bladder, lung and kid-
ney cancer, [7-14]. Data from epidemiological studies
also show that chronic exposure to arsenic contaminated
drinking water is associated with adverse reproductive
health effects [15-19]. These reproductive health studies
focused on the effect of arsenic on fetal loss, preterm
birth, and/or birthweight. None have reported on the ef-
fect of chronic arsenic exposure on maternal health.
We decided, therefore, to examine the association be-
tween arsenic exposure and maternal health, as assessed
by self-reported symptoms during pregnancy. We con-
ducted this study in a large population-based prospective
cohort of pregnant women recruited in Bangladesh. In
this prospective reproductive health cohort, women
were asked questions about their health and followed
throughout the course of their pregnancy. We hypothe-
sized that arsenic exposure measured in maternal drink-
ing water at the time of enrollment into the cohort
would be associated with increased self-reported symp-
toms of illness reported during the pregnancy.
Methods
Study area and subject selection
A prospective birth cohort was recruited in the Sirajdikhan
and Pabna Sadar Upazilas of Bangladesh from 2008–2011.
The objective of this cohort was to observe the effects of
chronic low level arsenic exposure on reproductive out-
comes. These Upazilas were selected for the study area
because a national survey conducted by the British
Geological Survey indicated that the average concentra-
tion of arsenic in the groundwater in these areas was more
moderate than other regions in Bangladesh yet spanned a
wide range of concentrations [6]. Additionally, Dhaka
Community Hospital Trust (DCH) operates rural health
clinics in these Upazilas that offer prenatal care and pro-
mote arsenic awareness by encouraging people to only
drink water from wells that comply with the Bangladesh
drinking water standard of≤50 μg As/L. In addition to
medical staff, each clinic has trained technicians who pro-
vided field testing of arsenic in well water upon request.
DCH has also worked with villages in these Upazilas to
implement safe water options [20].
Pregnant women were recruited by DCH-trained fe-
male community health care workers who live in the
villages serviced by the clinics. Heath care workers were
supplied with pregnancy test kits to identify potential
participants. Women with a positive pregnancy test were
told about the study and invited to the clinic to deter-
mine if they were eligible to participate in the study. Eli-
gibility criteria included: ≥18 years of age, ultrasound
confirmed singleton pregnancy of less than 16 weeks’
gestation, used a tubewell that supplied groundwater as
their primary drinking water source, planned to live at
their current residence for the duration of the preg-
nancy, planned to continue prenatal health care with
DCH, and agreed to deliver at DCH or at home with a
DCH-trained midwife.
The study involved four scheduled visits- at the time of
enrollment (V1), at 28-weeks gestational age (V2), delivery
(V3), and one month postpartum (V4). At V1 and V2, par-
ticipants were asked to come to the clinic where they
underwent a physical exam including an ultrasound and
completed detailed questionnaires regarding their medical,
pregnancy and drinking water histories. Participants also
provided biological samples for medical tests and trace
metal analysis. The medical questionnaires were also ad-
ministered at V4. This analysis uses information collected
in the medical questionnaire throughout the pregnancy
(V1, V2, and V4). Cross-sectional analyses that used all
data collected at V1 are included as Additional file 1: Sup-
plemental Tables 1 and 2. As an incentive for participa-
tion, all women were provided with free prenatal care
from DCH and prenatal vitamins that were replenished
during monthly checkups in the participants’ homes.
Of the 1,458 participants with a confirmed single preg-
nancy that have data currently available for analysis, 196
(13.4%) were lost to follow up. This left 1,262 partici-
pants who completed all study visits. Complete informa-
tion for all covariates was available for 1,165 of these
participants. Informed consent was obtained from all
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any study activities. During the consent procedure all
participants were informed of the hazards posed by ar-
senic exposure using language that was consistent with
the ongoing arsenic awareness campaigns (e.g. arsenic is
a poison found in the groundwater that causes diseases
of the skin and other parts of the body). Participants
were also informed on the intention of this study which
was to find out how arsenic affected the health of preg-
nant women and their infants. Participants were told
about safe water options which could differ depending
on their village circumstances [20]. Participants could
request that their water be tested for arsenic using
Merck (doubling method) field test kits by clinic staff
[21]. For those participants that requested a field test,
clinic staff made an appointment with the participant to
come to their home to test their water. Since the con-
sent process occurred during the first scheduled clinic
visit, all arsenic field tests occurred after participants
completed their initial questionnaires. Additionally, all
participants were informed of the concentration of
arsenic in their drinking water after it was analyzed by
inductively coupled plasma mass spectrometry. This
study was approved by the Human Research Commit-
tees at the Harvard School of Public Health, Dhaka
Community Hospital and Oregon State University.
Arsenic exposure
At the time of enrollment, a water sample was collected
from the tubewell each participant identified as their pri-
mary source of drinking water. Briefly, water samples
were collected in 50-ml polypropylene tubes (BD Falcon,
BD Bioscience, Bedford, MA) and preserved with Re-
agent Grade nitric acid (Merck, Germany) to a pH <2.
Samples were kept at room temperature prior to analysis
by inductively coupled plasma-mass spectrometry fol-
lowing US EPA method 200.8 (Environmental Labora-
tory Services, North Syracuse, New York). The average
percent recovery of As from PlasmaCAL multi-element
Quality Control standard #1 solution (SCP Science,
Canada) was 101% (range: 92%-110%). Of the 1237 sam-
ples included in this analysis, 252 (20.4%) had an arsenic
concentration below the 1 μg As/L limit of detection
(LOD). These samples were re-assigned half the value of
the LOD for statistical analysis.
Self-reported symptoms during pregnancy
The attending obstetrician asked the woman to recall
symptoms three times during their current pregnancy
(V1, V2, and V4). The questionnaire specifically asked
whether the woman experienced any of the following
groups of symptoms at least once during the time period
covered by the study visit: cold, flu, rubella or other
respiratory infections (yes/no); nausea and vomiting
(yes/no); abdominal cramps (yes/no); vaginal bleeding
(yes/no); swollen feet (yes/no); and severe headaches
(yes/no).
Covariates
At enrollment, information on women’s age, parity, educa-
tion, socioeconomic status, access to sanitation, smoking
history, medical and drinking water history, and informa-
tion on the child’s father was collected. Educational attain-
ment was collapsed into three categories (illiterate/able to
write name, primary education, secondary education or
higher). Parity was defined as the number of previous live
births in multiparous women. Economic status was
assessed directly by asking husbands their monthly income
(less than 3000 taka, 3000–5000 taka, greater than 5000
taka, and refused to answer). Gestational age was deter-
mined by ultrasound measurements taken at the time of
enrollment because few women could recall the date of
their last menstrual period. Women’sw e i g h ta n dh e i g h t
were measured at enrollment and at each follow up visit.
Body mass index (BMI) was calculated as weight divided by
height squared (kilograms per square meter). Hemoglobin
was estimated by mixing fresh whole blood with K3-EDTA
prior to analysis by an automated hematology analyzer
(Sysmex XS-800i, Sysmex India,). Anemia was defined as
having a hemoglobin level ≤12 g/dL. Erythrocyte ferritin
was measured in fresh blood and analyzed using an enzyme
immunoassay IMx-Ferritin kit and an IMx analyzer. Severe
ferritin deficiency was defined as ferritin <20 μg/L, mild
deficiency was defined as ferritin within 20–40 μg/L, and
no deficiency was defined as ferritin >40 μg/L.
Statistical analysis
General descriptive statistics were calculated for select
characteristics. Drinking water arsenic concentrations
were transformed using the natural log and also catego-
rized into quartiles. Chi-square tests and Wilcoxon rank
sum tests were used to assess the association between
outcomes and select characteristics. Logistic regression
models were used to compute the relative odds and
95% confidence intervals of experiencing a symptom at
least once during pregnancy for increasing quartiles of
arsenic. Additionally, we constructed logistic regression
models to compute the odds of self-reported symptoms
for arsenic concentrations dichotomized at regulatory
drinking water arsenic limits (below/above 10 μg/L and
below/above 50 μg/L). We used a parsimonious ap-
proach towards model building and only included covar-
iates in the multiple logistic regression models if they
were associated with any self-reported symptom with an
p<0.05.
Since medication usage during pregnancy could influ-
ence symptoms experienced during pregnancy, we con-
ducted a restricted analysis among women who reported
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tion during their pregnancy. Since the number of prior
pregnancies is considered a risk factor for nausea and
vomiting in pregnancy [22] we also examined potential
effect modification by parity by including an interaction
term between arsenic exposure and primiparous status.
Results
We compared socio-demographic characteristics between
the 1,262 women with complete follow up information
with the 196 women who were lost to follow up. There
was no significant difference in the age (22.8 vs 22.9 years,
p-value=0.51), ln drinking water arsenic (1.3 vs 1.7 μg/L,
p-value 0.27), parity (0.7 vs 0.7, p-value=0.76), BMI at the
time of enrollment (20.8 vs 20.5, p-value=0.42), or mater-
nal education (p-value=0.14) among participants who
were lost to follow up and those who were included in this
analysis. Clinic staff attempted to re-contact the women
who were lost to follow up by going to their homes to de-
termine why they did not complete the study protocols.
None of these women could be re-contacted so reasons
for lost to follow up could not be ascertained.
At the time of enrollment, the overall mean and me-
dian concentration of arsenic in participant’s drinking
water was 38 μg/L (standard deviation, 92.7 μg/L) and
2 μg/L (interquartile range, 30 μg/L), respectively. Sixty-
three percent of the women reported experiencing at
least one health symptom during their pregnancy. The
most common symptom reported by women was nau-
sea/vomiting (39.2%) followed by abdominal cramping
(37.1%), headache (32.7%), cold/flu/infection (18.0%), va-
ginal bleeding (1.0%), and swollen ankles (1.0%). Women
who reported having any symptom during pregnancy
were exposed to significantly higher concentrations of
arsenic in their water compared to women who reported
no symptoms (Table 1). Additionally, women who re-
ported any symptom during pregnancy were more likely
to be underweight, exposed to second hand tobacco
smoke, have lower educational attainment, have anemia
and lower ferritin status, lack sanitary latrines, take
medication, and have lower household incomes com-
pared to women who reported no adverse symptoms
during pregnancy.
Frequencies of specific symptoms by categories of ar-
senic exposure and select characteristics are presented
in Table 2. Overall, participants who reported nausea/
vomiting and abdominal cramping were exposed to
higher concentrations of arsenic in their drinking water
compared to women who did not report these symp-
toms. No difference in arsenic exposure was observed
between participants who reported cold/flu/respiratory
infection or severe headache compared to women who
did not report these symptoms. No difference in arsenic
exposure was observed between participants who reported
vaginal bleeding or swollen ankles. It should be noted that
only 12 participants reported vaginal bleeding or swollen
ankles resulting in small sample sizes that limited statistical
inference (data not shown).
The association between symptoms and quartiles of
arsenic exposure from adjusted logistic regression
models are presented in Table 3. The odds of a woman
reporting any symptom during pregnancy were higher
among those participants with the highest arsenic
concentration in their drinking water. There was a
significant trend for increasing odds of symptoms with
increasing arsenic exposure (P for trend <0.0001). Com-
pared to the lowest quartile of arsenic, the adjusted
odds ratio for any symptom during pregnancy was
0.62 (95% CI: 0.44, 0.88) for the second quartile, 1.83
(95% CI: 1.25, 2.69) for the third quartile, and 2.11
(95% CI: 1.42, 3.13) for the fourth quartile. Upon exam-
ining individual symptoms, only nausea/vomiting and
abdominal cramping showed consistent associations
with arsenic exposure. The odds of self-reported nausea/
vomiting was 0.98 (95% CI: 0.68, 1.41), 1.52 (95% CI: 1.05,
2.18), and 1.81 (95% CI: 1.26, 2.60) in the second, third
and fourth quartile of arsenic relative to the lowest
quartile after adjusting for age, body mass index, second-
hand tobacco smoke exposure, educational status, parity,
anemia, ferritin, medication usage, type of sanitation at
home, and household income. A significant increased
odds of abdominal cramping, on the other hand, was only
observed in the highest arsenic quartile (aOR: 1.62, 95%
CI: 1.13, 2.32) compared to the lowest quartile.
Table 4 shows the adjusted odds of self-reported
symptoms when arsenic exposure was dichotomized
below and above 50 μg/L. Among participants whose
drinking water contained arsenic greater than or equal
to 50 μg/L, odds of reporting any symptom were two-
fold higher than participants whose drinking water con-
tained less than 50 μg/L after adjusting for age, BMI,
second-hand tobacco exposure, educational status, par-
ity, anemia, ferritin, household sanitation, medication
usage, and household income (aOR: 2.11; 95% CI: 1.47,
3.02). The adjusted odds of nausea/vomiting (aOR: 1.47;
95% CI: 1.09, 1.98) and abdominal cramping (aOR: 1.79;
95% CI: 1.31, 2.45) was also significantly higher among
participants whose drinking water contained arsenic
≥50 μg/L compared <50 μg/L.
Table 5 shows the adjusted odds of self-reported
symptoms when arsenic exposure was dichotomized
below and above 10 μg/L. These results were consistent
with the previous analyses. The adjusted odds of report-
ing any symptom was approximately two-fold higher
than participants whose drinking water contained less
than 50 μg/L (aOR: 2.99; 95% CI: 2.21, 4.04). The ad-
justed odds of nausea/vomiting (aOR: 1.62; 95% CI: 1.25,
2.10) and abdominal cramping (aOR: 2.39; 95% CI: 1.83,
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symptoms (2008–2010)
Reporting any symptom
No (n=467) Yes (n= 795) p-value
Mean (SD), arsenic at enrollment (μg/L) 20.9 (70.8) 50.0 (104.1) <0.0001
Median (IQR), arsenic at enrollment (μg/L) 1.6 (0.8, 5.2) 7.0 (1.1, 58.0) <0.0001
a
Mean (SD) age at enrollment (yrs) 22.6 (4.0) 23.1 (4.3) 0.05
(n) % (n) %
Drinking water arsenic quartiles
Q4 (Mean: 144.7 μg/L, range: 32–1,400 μg/L) (68) 14.56 (244) 30.69 <0.0001
Q3 (Mean: 12.0 μg/L, range: 2.1–31 μg/L) (77) 16.49 (226) 28.43
Q2 (Mean: 1.5 μg/L; range: 0.9–2 μg/L (185) 39.61 (142) 17.86
Q1 (Mean: 0.7 μg/L; range: 0.5–0.89 μg/L) (137) 29.34 (183) 23.02
BMI at time of enrollment (kg/m2)
<18.5 (117) 25.05 (246) 30.94 0.05
18.5–24.9 (299) 64.03 (481) 60.5
≥ 25.0 (51) 10.92 (68) 8.55
Environmental tobacco smoke
Absent (319) 68.6 (418) 52.64 <0.001
Present (146) 31.4 (376) 47.36
Missing 2 1
Maternal education
Illiterate/Able to write name (47) 10.13 (144) 18.14 <0.0001
Primary education (199) 42.89 (216) 27.2
≥ Secondary education (218) 46.98 (434) 54.66
Missing 3 1
Parity
0 (214) 45.82 (309) 38.87 0.01
1-2 (213) 45.61 (385) 48.43
≥3 (40) 8.57 (101) 12.7
Anemia (hemoglobin≤12 g/dL)
No (327) 70.32 (647) 81.49 <0.0001
Yes (138) 29.68 (147) 18.51
Missing 2 1
Ferritin
Severe deficiency (<20 μg/L) (80) 18.06 (108) 14.3 0.0007
Mild deficiency (20–40 μg/L) (138) 31.15 (179) 23.71
None (>40 μg/L) (225) 50.79 (468) 61.99
Missing 24 40
Sanitation at home
Sanitary latrine (372) 79.83 (469) 59.14 <0.0001
Other (94) 20.17 (324) 40.86
Missing 12
Taking herbs/medication
No (459) 98.5 (719) 90.44 <0.0001
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whose drinking water contained arsenic ≥10 μg/L com-
pared to <10 μg/L. Interestingly, the adjusted odds of
cold/flu/infections was significantly lower among partici-
pants whose drinking water contained arsenic greater than
or equal to 10 μg/L compared to participants whose drink-
ing water contained less than 10 μg/L (aOR: 0.61, 95% CI:
0.43, 0.86).
We also examined the potential for effect modification
by parity and observed no significant interactions be-
tween parity status (primiparous vs multiparous) and
arsenic quartile for any symptom (p=0.78), nausea/
vomiting (p= 0.22) or abdominal cramping (p=0.61).
This indicated that the odds of reporting symptoms did
not differ between primigravid and multigravid partici-
pants in relationship to arsenic exposure.
To determine if taking medication during pregnancy
influenced the observed relationship between arsenic
and self-reported symptoms during pregnancy, we con-
ducted a restricted analysis (Table 6). In a subset of
women who did not report taking any prescription or
herbal medications during pregnancy (n =1,166), we ob-
served similar results where increasing arsenic exposure
was significantly associated with increased odds of any
symptom (p-value <0.001), nausea/vomiting (p-value =
0.0007), and abdominal cramping (p-value <0.0001).
However, there was no significant trend between arsenic
exposure and cold/flu/infection (p-value =0.39) or se-
vere headaches (p-value =0.37). Similar associations
were also observed when the analysis was restricted to
only live births (data not shown).
Discussion
We observed that the likelihood that a women reported
adverse health symptoms during pregnancy increased with
higher arsenic exposure. Specifically, the odds of nausea/
vomiting and abdominal cramping were significantly
higher among participants in the third quartile and fourth
quartile. This is noteworthy because the mean arsenic
concentration in the third quartile was 12 μg As/L (range,
2.1-31 μg As/L). Not only is this concentrations of arsenic
commonly observed in potable groundwater, this water
would be considered safe to drink in Bangladesh because
it is below the current recommended level of 50 μg As/L.
It is plausible that women whose tubewell met the current
recommendations in Bangladesh would be less likely to
consider their drinking water to be problematic and subse-
quently this group may be less inclined to exaggerate
symptomology relating to the arsenic levels in their water
source compared to participants whose drinking water did
not meet the Government’s recommendations.
Nausea/vomiting and abdominal cramping are com-
mon ailments in pregnancy and will range in severity
[23,24]. While these symptoms tend to resolve during
pregnancy and are frequently considered an expected as-
pect of pregnancy, nausea/vomiting during pregnancy
are linked with maternal distress and contribute to ma-
ternal morbidity [25-29]. In Sri Lanka, nausea/vomiting
have been shown to be the leading cause of lost house-
hold productivity among pregnant women [9]. Nausea/
vomiting is also highly correlated with maternal anxiety,
maternal depression, and contribute to a reduction in
maternal quality of life [27,30,31]. Data from studies that
examined the relationship between nausea/vomiting and
infant birthweight are inconsistent with some studies
showing no relationship with birthweight and some
reporting that severe nausea/vomiting was associated
with decreased birthweight [32,33].
Our finding that arsenic exposure is related to nausea/
vomiting during pregnancy increases our understanding
of the etiology of this pregnancy-related condition.
Studies in other populations also report that nausea/
vomiting during pregnancy is more common in younger
women, primigravidas, and obese women although these
associations were not observed in our population [22].
Researchers have also reported that nausea during preg-
nancy is related to human chorionic gonadotropin levels,
and the absence of these symptoms in early pregnancy
may be sign of poor implantation or miscarriage [34].
However, our study includes measures of nausea/
Table 1 Characteristics of 1,262 participants that reported experiencing any symptom during pregnancy versus no
symptoms (2008–2010) (Continued)
Yes (7) 1.5 (76) 9.56
Missing 1 0
Income (taka/month)
<3000 (45) 9.89 (176) 22.34 <0.0001
3001–5000 (270) 59.34 (412) 52.28
≥ 5000 (137) 30.11 (175) 22.21
Refused/don’t know (3) 0.66 (25) 3.17
Missing 12 7
aWilcoxon test performed on natural log transformed values.
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Cold/Flu/infection Nausea/vomiting Abdominal cramping Headache
No (n= 1035) Yes (n=227) p-value No (n=762) Yes (n= 500) p-value No (n=794 ) Yes (n= 468) p-value No (n=850) Yes (n=412) p-value
Median (IQR) ln
arsenic (μg/L)
0.69 (−0.13, 3.47) 0.53
(−0.15, 2.83)
0.11 0.59 (−0.19, 2.91) 1.96
(0.18, 4.11)
<0.001 0.59
(−0.17, 2.71)
2.39
(0.18, 4.21)
<0.001 0.64
(−0.11, 3.26)
1.02 (−0.15, 3.81) 0.23
Mean (SD) age (yrs) 22.8 (4.1) 23.1 (4.6) 0.46 22.7 (4.1) 23.1 (4.4) 0.09 22.8 (4.2) 23 (4.1) 0.56 22.9 (4.2) 22.8 (4.1) 0.73
(n) % (n) % (n) % (n) % (n) % (n) % (n) % (n) %
Drinking water
arsenic quartiles
Q4 (High) (264) 25.51 (48) 21.15 0.26 (152) 19.95 (160) 32.0 <0.001 (150) 18.89 (162)34.62 <0.001 (195) 22.94 (117) 28.4 0.04
Q3 (249) 24.06 (54) 23.79 (163) 21.39 (140) 28.0 (163) 20.53 (140) 29.91 (205) 24.12 (98) 23.79
Q2 (260) 25.12 (67) 29.52 (231) 30.31 (96) 19.2 (262) 33.0 (65) 13.89 (239) 28.12 (88) 21.36
Q1 (Low) (262) 25.31 (58) 25.55 (216) 28.35 (104) 20.8 (219) 27.58 (101) 21.58 (211) 24.82 (109) 26.46
BMI (kg/m2)
<18.5 (295) 28.5 (68) 29.96 0.07 (206) 27.03 (157) 31.4 0.24 (214) 26395 (149) 31.84 0.10 (243) 28.59 (120) 29.13 0.87
18.5-24.9 (651) 62.9 (129) 56.83 (481) 63.12 (299) 59.8 (498) 62.72 (282) 60.26 (529) 62.24 (251) 60.92
≥ 25.0 (89) 8.6 (30) 13.22 (75) 9.84 (44) 8.8 (82) 10.33 (37) 7.91 (78) 9.18 (41) 9.95
Second hand smoke
Absent (622) 60.27 (115) 50.66 0.008 (487) 64.16 (250) 50.0 <0.001 (485) 61.24 (252) 53.96 0.01 (524) 61.79 (213) 51.82 0.0008
Present (410) 39.73 (112) 49.34 (272) 35.84 (250) 50.0 (307) 38.76 (215) 46.04 (324) 38.21 (198) 48.18
Num. missing 3 0 3 0 2 1 2 1
Maternal education
Illiterate/able to
write name
(150) 14.55 (41) 18.06 0.41 (88) 11.59 (103) 20.64 <0.0001 (110) 13.91 (81) 17.34 0.01 (122) 14.4 (69) 16.79 0.02
Primary education (343) 33.27 (72) 31.72 (295) 38.87 (120) 24.05 (284) 35.9 (131) 28.05 (302) 35.66 (113) 27.49
≥ Secondary education (538) 52.18 (114) 50.22 (376) 49.54 (276) 55.31 (397) 50.19 (255) 54.6 (423) 49.94 (229) 55.72
Num. missing 4 0 3 1 3 1 3 1
Parity
0 (430) 41.55 (93) 40.97 0.98 (323) 42.39 (200) 40.0 0.06 (348) 43.83 (175) 37.39 0.06 (347) 40.82 (176) 42.72 0.75
1-2 (490) 47.34 (108) 47.58 (367) 48.16 (231) 46.2 (365) 45.97 (233) 49.79 (405) 47.65 (193) 46.84
≥ 3 (115) 11.11 (26) 11.45 (72) 9.45 (69) 13.8 (81) 10.2 (60) 12.82 (98) 11.53 (43) 10.11
Anemia (hemoglobin
≤12 g/dL)
No (802) 77.71 (172) 75.77 0.53 (569) 74.87 (405) 81.16 0.009 (572) 72.22 (402) 86.08 <0.0001 (652) 76.89 (322) 78.35 0.56
Yes (230) 22.29 (55) 24.23 (191) 25.13 (94) 18.84 (220) 27.78 (65) 13.92 (196) 23.11 (89) 21.65
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9Table 2 Associations specific symptoms and select characteristics of 1,262 mothers that were followed throughout pregnancy (2008–2010) (Continued)
Num. missing 3 0 2 1 2 1 2 1
Serum ferritin
Severe deficiency
(<20 μg/L)
(159) 16.21 (29) 13.36 0.55 (122) 16.87 (66) 13.89 <0.0001 (132) 17.79 (56) 12.28 0.02 (137) 16.81 (51) 13.32 0.01
Mild deficiency
(20–40 μg/L)
(260) 26.5 (57) 26.27 (221) 30.57 (96) 20.21 (199) 26.82 (118) 25.88 (230) 28.22 (87) 22.72
None (>40 μg/L) (562) 57.29 (131) 60.37 (380) 52.56 (313) 65.89 (411) 55.39 (282) 61.84 (448) 54.97 (245) 63.97
Num. missing 54 10 39 25 52 12 35 29
Sanitation at home
Sanitary latrine (715) 69.22 (126) 55.75 <0.0001 (542) 71.32 (299) 59.92 <0.0001 (580) 73.23 (261) 55.89 <0.0001 (601) 29.04 (240) 58.25 <0.0001
Other (318) 30.78 (100) 44.25 (218) 28.68 (200) 40.08 (212) 26.77 (206) 44.11 (246) 29.04 (172) 41.75
Num. missing 21 21 2 1 30
Taking herbs/medication
No (988) 95.55 (190) 83.7 <0.0001 (739) 97.11 (439) 87.8 <0.0001 (763) 96.22 (415) 88.68 <0.0001 (818) 96.35 (360) 87.38 <0.0001
Yes (46) 4.45 (37) 16.3 (22) 2.89 (61) 12.2 (30) 3.78 (53) 11.32 (31) 3.65 (52) 12.62
Num. missing 1 0 1 0 1 0 1 0
Income (taka/month)
<3000 (185) 18.17 (36) 16.0 0.70 (111) 14.84 (110) 22.22 <0.0001 (97) 12.47 (124) 26.67 <0.0001 (133) 15.95 (88) 21.52 0.006
3001-5000 (558) 54.81 (124) 55.11 (422) 56.42 (260) 52.53 (451) 57.97 (231) 49.68 (474) 56.83 (208) 50.86
≥ 5000 (254) 24.95 (58) 25.78 (203) 27.14 (109) 22.02 (215) 27.63 (97) 20.86 (214) 25.66 (98) 23.96
Refused/don’t know (21) 2.06 (7) 3.11 (12) 1.6 (16) 3.23 (15) 1.93 (13) 2.8 (13) 1.56 (15) 3.67
Num. missing 17 2 14 5 16 3 16 3
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9Table 3 Associations between quartiles of arsenic exposure and odds of self-reported symptoms during pregnancy for women that were followed throughout
pregnancy
Any symptom Cold/flu/infection Nausea/vomiting Abdominal cramping Headache
Crude OR aOR Crude OR aOR Crude OR aOR Crude OR aOR Crude OR aOR
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
Water arsenic
Q4 (High) 2.69 (1.90–3.81) 2.11 (1.42–3.13) 0.82 (0.54–1.25) 0.71 (0.45–1.14) 2.19 (1.58–3.02) 1.81 (1.26–2.60) 2.34 (1.69–3.24) 1.62 (1.13–2.32) 1.16 (0.84–1.61) 1.11 (0.77–1.90)
Q3 2.20 (1.56, 3.09) 1.83 (1.25–2.69) 0.98 (0.65–1.48) 0.88 (0.55–1.39) 1.78 (1.29–2.47) 1.52 (1.05–2.18) 1.86 (1.34–2.58) 1.31 (0.91–1.88) 0.93 (0.66–1.29) 0.86 (0.59–1.25)
Q2 0.58 (0.42–0.78) 0.62 (0.44–0.88) 1.16 (0.79–1.72) 1.30 (0.85–1.99) 0.86 (0.62–1.21) 0.98 (0.68–1.41) 0.54 (0.38–0.77) 0.55 (0.37–0.81) 0.71 (0.51–1.00) 0.77 (0.53–1.10)
Q1 (Low) 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
Test for trend <0.0001 <0.0001 0.42 0.08 <0.0001 0.001 <0.0001 <0.0001 0.04 0.19
Adjusted models include age, BMI, second-hand smoke exposure, maternal educational status, parity, anemia status, ferritin status, type of sanitation used
at home, use of herbal remedy or medication, and household income. The average arsenic concentration and range for each quartile is: Q4 = 144.7 μg/L
(32 μg/L – 1,400 μg/L); Q3 = 12.0 μg/L (2.1 μg/L – 31 μg/L); Q2 = 1.5 μg/L (0.9 μg/L – 2.0 μg/L); and Q1 = 0.7 μg/L (0.5 μg/L – 0.89 μg/L).
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9vomiting through the second and third trimester which
is not likely to represent implantation, an early event in
pregnancy. Also, we observed a consistent association
between higher levels of arsenic exposure and nausea/
vomiting among only those pregnancies that resulted in
live birth.
While others have reported that nausea is common in
individuals who experienced acute arsenic poisoning
[35-37] this study contributes new evidence that chronic
arsenic exposure at relatively moderate concentrations
are associated with increased risk of nausea [38]. We ob-
serve, however, that relatively modest arsenic concentra-
tions in drinking water were associated with increased
odds of nausea/vomiting and abdominal cramping dur-
ing pregnancy. Our study has many strengths including
the ascertainment of arsenic exposure early in pregnancy
from personal drinking water samples, confirmed single-
ton pregnancies, and the ability to control for many
confounders including second-hand smoke exposure,
sanitary conditions, medication usage, and others. Fur-
thermore, our findings remained consistent when we
accounted for the potential effect of parity and medica-
tion usage. The potential for bias for self-reported ma-
ternal symptoms is limited because the prospective
analyses yielded very similar results to cross-sectional
analyses conducted at the time of enrollment using all
available data (Additional file 1: Supplemental Tables S1
and S2). Also, participants were asked three times
throughout their pregnancy to report any symptoms.
Additionally, participants did not know the concentra-
tion of arsenic in their drinking water prior to enrolling
in the study. It is possible, however, that participants had
previously tested their water for arsenic and this know-
ledge may have resulted in differential report of maternal
symptoms. However, the higher odds of nausea/vomiting
were observed at arsenic concentrations below the
current Bangladesh drinking water recommendations
and subsequently the well would be considered an ac-
ceptable source of potable water.
Conclusion
We observed a positive exposure-response relation-
ship between arsenic concentrations in drinking
water and self-reported nausea/vomiting and abdom-
inal cramping during pregnancy in a prospective co-
hort of pregnant women recruited in Bangladesh.
These data provide additional evidence that arsenic-
contaminated drinking water at moderate concentra-
tions adversely affects maternal and reproductive
health. Continued efforts to reduce arsenic exposure
in Bangladesh are warranted particularly for women
of reproductive age.
Table 4 Association between arsenic exposure categorized above/below 50 μg/l and self-reported symptoms during
pregnancy in 1,262 women recruited in Bangladesh from multiple logistic regression models (2008–2011)
Any symptom Cold/flu/infection Nausea/vomiting Abdominal cramping Severe headache
Crude OR Adjusted OR Crude OR Adjusted OR Crude OR Adjusted OR Crude OR Adjusted OR Crude OR Adjusted OR
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
Water
arsenic
Above
50 μg/L
2.76
(1.98, 3.83)
2.11
(1.47, 3.02)
0.87
(0.60, 1.26)
0.78
(0.52, 1.16)
1.85
(1.40, 2.43)
1.47
(1.09, 1.98)
2.19
(1.63, 2.94)
1.79
(1.31, 2.45)
1.34
(1.01, 1.78)
1.25
(0.92, 1.71)
Below
50 μg/L
1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Adjusted models include age, BMI, second-hand smoke exposure, maternal educational status, parity, anemia status, ferritin status, type of sanitation used at
home, use of herbal remedy or medication, and household income.
Table 5 Association between arsenic exposure categorized above/below 10 μg/l and self-reported symptoms during
pregnancy in 1,262 women recruited in Bangladesh from multiple logistic regression models (2008–2011)
Any symptom Cold/Flu/Infection Nausea/Vomiting Abdominal cramping Severe headache
Crude OR Adjusted OR Crude OR Adjusted OR Crude OR Adjusted OR Crude OR Adjusted OR Crude OR Adjusted OR
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
Water
arsenic
Above
10 μg/L
3.57
(2.73, 4.66)
2.99
(2.21, 4.04)
0.73
(0.54, 0.99)
0.61
(0.43, 0.86)
2.02
(1.60, 2.55)
1.62
(1.25, 2.10)
2.83
(2.20, 3.64)
2.39
(1.83, 3.13)
1.30
(1.02, 1.65)
1.14
(0.87, 1.50)
Below
10 μg/L
1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Adjusted models include age, BMI, second-hand smoke exposure, maternal educational status, parity, anemia status, ferritin status, type of sanitation used at
home, use of herbal remedy or medication, and household income.
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http://www.ehjournal.net/content/13/1/29Table 6 Associations between quartiles of arsenic exposure and odds of self-reported symptoms during pregnancy in a subpopulation of women who did not
report taking prescription or herbal medication during pregnancy (N= 1,166)
Any symptom Cold/flu/infection Nausea/vomiting Abdominal cramping Headache
Water
arsenic
Crude OR aOR Crude OR aOR Crude OR aOR Crude OR aOR Crude OR aOR
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
Q4 (High) 2.84 (1.98–4.07) 2.33 (1.56–3.50) 0.79 (0.50–1.27) 0.79 (0.47–1.31) 2.17 (1.54–3.06) 1.86 (1.27–2.71) 2.49 (1.77–3.51) 1.80 (1.23–2.62) 1.14 (0.81–1.62) 1.09 (0.74–1.61)
Q3 2.35 (1.66, 3.34) 2.06 (1.39–3.05) 0.96 (0.61–1.51) 0.91 (0.55–1.51) 1.78 (1.27–2.51) 1.55 (1.06–2.27) 1.96 (1.39–2.76) 1.45 (0.99–2.13) 0.97 (0.68–1.38) 0.91 (0.61–1.35)
Q2 0.60 (0.44–0.83) 0.64 (0.45–0.92) 1.30 (0.86–1.98) 1.47 (0.94–2.32) 0.86 (0.61–1.22) 0.94 (0.64–1.37) 0.55 (0.37–0.80) 0.55 (0.37–0.83) 0.72 (0.50–1.02) 0.79 (0.54–1.16)
Q1 (Low) 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
Test for trend <0.0001 <0.0001 0.13 0.39 <0.0001 0.0007 <0.0001 <0.0001 0.04 0.37
Adjusted models include age, BMI, second-hand smoke exposure, maternal educational status, parity, anemia status, ferritin status, type of sanitation used
at home, use of herbal remedy or medication, and household income. The average arsenic concentration and range for each quartile is: Q4 = 142.8 μg/L
(32 μg/L – 1,400 μg/L); Q3 = 11.9 μg/L (2.1 μg/L – 31 μg/L); Q2 = 1.5 μg/L (0.9 μg/L – 2.0 μg/L); and Q1 = 0.7 μg/L (0.5 μg/L – 0.89 μg/L).
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9Additional file
Additional file 1: Table S1. Cross-sectional Bivariate Associations
Between Quartiles of Arsenic Exposure and Odds of Self-Reported
Symptoms Described At Enrollment in 1,458 Women Recruited Into
A Prospective Study in Bangladesh (2008-2010). The average arsenic
concentration and range for each quartile is: Q4 = 139.7 μg/L (28.9 μg/
L – 1,400 μg/L); Q3 = 10.5 μg/L (2.0 μg/L – 28 μg/L); Q2 = 1.5 μg/L (0.9
μg/L – 1.9 μg/L); and Q1 = 0.71 μg/L (0.5 μg/L – 0.87 μg/L). Table S2.
Cross-sectional Associations Between Quartiles of Arsenic Exposure and
Adjusted Odds of Self-Reported Symptoms Described At Enrollment in
1,347 Pregnant Women Who Participated in A Prospective Study in
Bangladesh With Complete Information For Age, BMI, Second-Hand
Tobacco Smoke Exposure, Maternal Education, Parity, Anemia Status,
Ferritin Status, Use of Herbs or Medication During Pregnancy, Type of
Sanitation Used at Home, and Household Income. The average arsenic
concentration and range for each quartile is: Q4 = 140.9 μg/L (28.9 μg/L –
1,400 μg/L); Q3 = 10.5 μg/L (2.0 μg/L – 28 μg/L); Q2 = 1.5 μg/L (0.9 μg/L –
1.9 μg/L); and Q1 = 0.7 μg/L (0.5 μg/L – 0.87 μg/L). Table S3. Cross-
sectional Association Between Arsenic Exposure Categorized Above/Below
50 μg/L and Odds of Self-Reported Symptoms Described At Enrollment.
Adjusted Odds Ratios Control For Age, BMI, Second-Hand Tobacco Smoke
Exposure, Maternal Education, Parity, Anemia Status, Ferritin Status, Use of
Herbs or Medication During Pregnancy, Type of Sanitation Used at Home,
and Household Income. Table S4. Cross-sectional Associations Between
Arsenic Exposure Categorized Above/Below 10 μg/L and Odds of
Self-Reported Symptoms Described At Enrollment. Adjusted Odds Ratios
Control For Age, BMI, Second-Hand Tobacco Smoke Exposure, Maternal
Education, Parity, Anemia Status, Ferritin Status, Use of Herbs or Medication
During Pregnancy, Type of Sanitation Used at Home, and Household
Income.
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